Beyfortus 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FXP8L
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,841
Award facts
- Contract value 100% obligated
- $19,840.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Beyfortus 100 mg/ml syringes. This firm fixed-price delivery order, valued at $19,840.92, is scheduled for completion by October 31, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting open competition among qualified vendors. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion vehicle that extends through December 2026 and serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is well-positioned to fulfill this requirement through its extensive federal contract portfolio with the Defense Logistics Agency. The company's primary IDC with DLA Troop Support Medical enables it to supply a broad range of pharmaceutical products, vaccines, and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. Beyfortus, a respiratory syncytial virus immunoglobulin monoclonal antibody, represents a specialized pharmaceutical commodity within the company's demonstrated capability to deliver critical medical products to federal customers across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26FXP8L?
SPE2DR26FXP8L was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on October 30, 2025.
How much is contract SPE2DR26FXP8L worth?
The government has obligated $19,841 on SPE2DR26FXP8L.
Is contract SPE2DR26FXP8L an order under another contract?
Yes. SPE2DR26FXP8L is a delivery order under SPE2DR25D6029, an indefinite delivery contract.
Was contract SPE2DR26FXP8L competed?
The extent of competition for SPE2DR26FXP8L was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award